Literature DB >> 16414554

Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study.

Larry F Chu1, David J Clark, Martin S Angst.   

Abstract

UNLABELLED: There is accumulating evidence that opioid therapy might not only be associated with the development of tolerance but also with an increased sensitivity to pain, a condition referred to as opioid-induced hyperalgesia (OIH). However, there are no prospective studies documenting the development of opioid tolerance or OIH in patients with chronic pain. This preliminary study in 6 patients with chronic low back pain prospectively evaluated the development of tolerance and OIH. Patients were assessed before and 1 month after initiating oral morphine therapy. The cold pressor test and experimental heat pain were used to measure pain sensitivity before and during a target-controlled infusion with the short-acting mu opioid agonist remifentanil. In the cold pressor test, all patients became hyperalgesic as well as tolerant after 1 month of oral morphine therapy. In a model of heat pain, patients exhibited no hyperalgesia, although tolerance could not be evaluated. These results provide the first prospective evidence for the development of analgesic tolerance and OIH by using experimental pain in patients with chronic back pain. This study also validated methodology for prospectively studying these phenomena in larger populations of pain patients. PERSPECTIVE: Experimental evidence suggests that opioid tolerance and opioid-induced hyperalgesia might limit the clinical utility of opioids in controlling chronic pain. This study validates a pharmacologic approach to study these phenomena prospectively in chronic pain patients and suggests that both conditions do occur within 1 month of initiating opioid therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16414554     DOI: 10.1016/j.jpain.2005.08.001

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  101 in total

Review 1.  Pharmacologic therapies for complex regional pain syndrome.

Authors:  Sean Mackey; Steven Feinberg
Journal:  Curr Pain Headache Rep       Date:  2007-02

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

4.  Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients.

Authors:  Caroline A Arout; Andrew J Waters; R Ross MacLean; Peggy Compton; Mehmet Sofuoglu
Journal:  Psychopharmacology (Berl)       Date:  2018-12-18       Impact factor: 4.530

5.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

6.  Reduced cold pain tolerance in chronic pain patients following opioid detoxification.

Authors:  Jarred Younger; Peter Barelka; Ian Carroll; Kim Kaplan; Larry Chu; Ravi Prasad; Ray Gaeta; Sean Mackey
Journal:  Pain Med       Date:  2008-06-18       Impact factor: 3.750

7.  Opioid-Induced Hyperalgesic Priming in Single Nociceptors.

Authors:  Eugen V Khomula; Dionéia Araldi; Ivan J M Bonet; Jon D Levine
Journal:  J Neurosci       Date:  2020-11-17       Impact factor: 6.167

Review 8.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

9.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

10.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.